The molecular diagnostics company licensed intellectual property from Washington University and Max Delbrück Center to advance circular RNA-based biomarker testing.
Circular Genomics has finalized exclusive intellectual property licensing agreements with Washington University in St. Louis and the Max Delbrück Center to advance development of a blood-based test for Alzheimer’s disease using circular RNA biomarkers.
The agreements provide the San Diego-based molecular diagnostics company with exclusive commercial rights to foundational IP covering the identification, measurement, and clinical application of circular RNA biomarkers across all stages of Alzheimer’s disease, from early preclinical phases through symptomatic disease.
Circular RNAs are RNA molecules that are highly concentrated in brain tissue, resistant to degradation in blood, and increasingly linked to neurodegenerative disease biology. These characteristics make them suitable candidates for Alzheimer’s testing, where long preclinical phases and subtle molecular changes have historically limited diagnostic innovation.
“These licenses represent a major strategic milestone for Circular Genomics,” says Paul Sargeant, PhD, chief executive officer of Circular Genomics, in a release. “Securing exclusive commercial rights from two of the most respected institutions in neurodegenerative research strengthens our long-term competitive position and underscores the scientific rigor behind our circRNA platform.”
Addressing Diagnostic Challenges
Current Alzheimer’s diagnosis often occurs late in disease progression and relies on invasive or costly procedures. Circular Genomics is developing a minimally invasive, blood-based circular RNA test designed to enable earlier detection and improved disease characterization.
The company plans to integrate the licensed technologies into its ongoing development programs and pursue FDA regulatory pathways as it advances toward clinical validation and commercialization. The IP agreements are expected to accelerate assay development and strengthen future regulatory submissions.
The licensed intellectual property complements Circular Genomics’ internal biomarker discovery and validation efforts. The company expects these assets to increase strategic value for biopharma partners seeking diagnostic solutions in neurology.
Supporting Precision Medicine Applications
Beyond diagnostic applications, the blood-based test is being designed for potential use in patient stratification and clinical trial enablement, supporting future precision medicine applications in Alzheimer’s care.
The agreements significantly expand Circular Genomics’ proprietary estate and support the company’s strategy to build a precision diagnostics platform in neurology. Both Washington University in St. Louis and the Max Delbrück Center are recognized leaders in Alzheimer’s disease research.
Circular Genomics focuses on developing blood-based tests using circular RNA biomarkers for neurodegenerative diseases. The company combines proprietary biology and advanced analytics in its clinically driven development approach for neurological disease diagnosis and management.
ID 53079478 © Kiosea39 | Dreamstime.com
